A scientist surrounded by vials and beakers in a modern laboratory, proudly displaying a vaccine. YTD Return: -44.88% Moderna, Inc. (NASDAQ:MRNA) is a biotechnology company specializing in ...

Moderna, Inc. (NASDAQ:MRNA) is a biotechnology company focused on the discovery, development, and commercialization of ...

In this case Moderna’s mRNA-1273 vaccine instructs the body to make antibodies against a stabilised form of the Spike (S) protein found on the SARS-CoV-2 virus.

Opinions expressed by Forbes Contributors are their own. Randy Bean is a noted Senior Advisor, Author, Speaker, Founder, & CEO. While the application of data and AI holds the potential to ...

coming after a September update in which Moderna announced cost cuts and pipeline cuts and lowered guidance, triggering a wave of analyst downgrades and worries about the biotech company’s ...

Most of what I just said about BioNTech applies to Moderna (NASDAQ: MRNA), too. This biotech stock looks like a bargain -- and not because its share price hovers around $42. Like BioNTech ...

Investors aren't giving Moderna much credit for its promising pipeline, either. The biotech company has nine late-stage programs, including a combination flu/COVID-19 vaccine, a cytomegalovirus ...

In the third quarter, Moderna reported $1.9 billion in revenue, roughly flat compared to the year-ago period. On the bottom line, the biotech reported net earnings per share of $0.03 compared to a ...

(MENAFN- Investor Ideas) CAMBRIDGE, Mass - July 27, 2020 (Investorideas Newswire) Coronavirus / Biotechnology ... laboratory and lifecycle management services. PPD supported the Phase 2 study for ...

Moderna opened its new global headquarters in June, consolidating its Cambridge operations into one six-floor, 462,000-square-foot office and lab building ... 100-employee biotech opens new ...